Sermorelin once had approval to treat children

The brief answer: pharmacy-made sermorelin has no adult approval

Can a pharmacy make sermorelin for a prescription today? The FDA allows preparation under temporary rules, while the pharmacy meets the rules' conditions.

Doctors once used the approved drug to test growth-hormone release. The approval later included treating children short of that hormone ^[10][11].

2008: the manufacturer stopped selling the approved drug in the US. That business decision wasn't a finding of failed treatment or harm.

Pharmacies now prepare prescriptions under rules the FDA calls Category 1. The FDA doesn't plan to stop that work while pharmacies follow the rules.

Each pharmacy-made drug hasn't passed the FDA approval tests for a particular illness. The temporary rules apply for now, but they don't promise you that the pharmacy will always be able to make the same prescription under the same conditions in the years ahead.

January 2025: the FDA finished its written instructions for this temporary policy. Finishing the instructions didn't turn the policy into permanent drug approval.

At the October 2024 review, CJC-1295 didn't receive the same pharmacy support. Drugs that both raise growth hormone can still face different rules.

Sermorelin asks the gland to release hormone while the body's usual limits remain active. Those limits don't prove healthy-aging benefits for you.

2008: a medical opinion article found too little evidence for preventing or treating aging ^[9]. Later trial findings haven't settled that concern.

The child findings belong to children who needed more growth hormone. They don't establish better strength, energy, or daily health in older people.

Sermorelin copies part of a hormone that prompts growth

Sermorelin is a smaller copy of the natural hormone used to prompt growth-hormone release. The copy uses fewer amino acids, the tiny joined parts that form proteins.

Scientists changed one end so the shortened copy could work fully. That change lets the smaller copy still prompt growth-hormone release.

This describes what the drug asks the gland to do. Full action doesn't mean a full health benefit or better sleep for you.

The four changes in CJC-1295 slow breakdown; sermorelin lacks those changes. Sermorelin also doesn't attach to albumin, a protein blood already carries.

The body therefore clears sermorelin much more quickly. Clearing sooner doesn't establish whether treatment is safe at your age.

2008: sales of the approved drug ended for business reasons ^[10]. The decision wasn't a finding that the drug harmed children or failed to help them.

CLINICAL ACCESS / EDITORIAL BOUNDARY

Access is a separate layer of the record

Outside the literature ledger, Promise Peptides (mypromise.com) has begun prescribing sermorelin; its prescription-only care includes an individual assessment, and its licensed U.S. clinicians reject requests they consider unsuitable. That decision belongs to the clinical encounter, not to this desk. Its care is for U.S. patients alone, and its state coverage and treatment choices have separate limits. A compounded sermorelin preparation has no FDA approval.

The body can still limit further hormone release

Sermorelin asks the gland to make and release growth hormone ^[1]. The shot itself doesn't contain growth hormone.

The liver's growth protein helps tell the body when enough has been released. Another hormone slows further release from the gland.

Those limits keep working while sermorelin prompts hormone release in bursts. They explain what the drug does, without proving safety over years.

A medical opinion article suggested an advantage for adults short of growth hormone ^[10]. The author compared sermorelin with a shot that supplies growth hormone directly, which gives the body hormone from outside instead of asking the gland to release the hormone the body makes.

That argument hasn't been settled by a trial comparing the treatments. An explanation of how a drug works isn't enough to predict your benefit.

The gland cannot release more growth hormone than the gland can make. Hormone rises can therefore be lower than with direct growth-hormone shots.

Very little sermorelin reaches blood when given through the nose. Swallowed sermorelin can break down in the gut before reaching blood.

Sermorelin also passes poorly through the lining under the tongue. A product claim doesn't prove enough reaches your blood or improves your health.

Children grew faster; the older-adult trial used a different drug

Sermorelin has trials behind its old child-treatment approval. CJC-1295 never reached that stage; findings still belong to the drug tested.

Children short of growth hormone grew faster. A study at several clinics tested children who hadn't reached puberty ^[11].

During daily study shots under the skin, growth rose from about 4.1 centimeters per year to about 7-8 centimeters per year. The researchers judged that the liver's growth protein hadn't risen too high.

That judgment wasn't a guarantee against every possible harm. The child results don't show that treatment would help you age well.

The older-adult study used tesamorelin, not sermorelin. The researchers enrolled 152 adults, including 66 with mild thinking or memory trouble ^[8].

The study ran for 20 weeks with 1 milligram daily before bed. A milligram is a thousandth of a gram; this was a study amount, not an instruction for your care.

Chance decided who received tesamorelin and who received a placebo, a shot without active drug. The adults and people checking the results didn't know which shot each person received.

Planning and managing tasks improved most clearly in the thinking tests. The liver's growth protein rose 117%, but stayed within the range expected in normal blood tests.

The adults also lost body fat during that trial. Researchers called unwanted effects mild, without naming those symptoms in this finding.

More than doubling a blood-test reading can still leave the reading in the normal range if the starting value is low enough, but the rise doesn't establish safety for you. Tesamorelin's results don't prove that sermorelin gives the same benefit.

2008: a medical opinion article questioned use against aging. The author judged that the evidence didn't justify preventing or treating aging ^[9].

A claim about your later years needs studies of that claim. Faster child growth cannot settle adult health benefits.

Another medical opinion article favored keeping natural limits on hormone release. The author suggested an advantage over direct growth-hormone shots ^[10].

A completed trial hasn't settled that comparison of treatments. The argument gives researchers a reason to test the difference.

2025: a review covered the hormone and drugs copying its action. The authors discussed possible uses and unanswered treatment questions ^[1].

People describe sleep changes, but years of safety remain unknown

People using sermorelin for research, including clinic users, describe changes. These accounts tell you what people noticed; studies comparing treatment with no active drug haven't confirmed that sermorelin caused the reported changes.

Users mention sleep, energy, appearance, and discomfort. Personal reports cannot separate the drug from other changes in someone's life.

• Sleep seemed sounder, with more vivid dreams: People often describe this within one to two weeks of reported nightly use.

Growth hormone rises during deep sleep, but that doesn't confirm better sleep from the drug.

• Daytime energy felt steadier and exercise left less soreness: People often connect these changes with better sleep.

They describe a gradual change, rather than a sudden burst of energy.

• Waist fat seemed to shrink over months: Clinic accounts describe modest changes over roughly 12 weeks.

Different meals, exercise, and health can make the cause hard to separate.

• Muscles looked firmer or skin felt different: Some people describe changes after months of nightly use.

Sleep and exercise can also change appearance and how skin feels.

• There was little change in the first month or two: Some people say they noticed nothing clear at first.

Waiting longer doesn't establish that continued use would be safe.

• Skin where the shot went became red, itchy, or swollen: People often describe mild discomfort that faded within hours.

Some moved the next shot to another spot; these reports don't establish that moving the shot helped or was safe.

• Headache, flushing, dizziness, or an upset stomach followed: People often mention these in the first week or two.

Many say the feelings passed as time went on.

• The body seemed puffy or swollen: People linked the swelling to holding salt and water.

Some reported less swelling than with CJC-1295 DAC; that comparison doesn't prove which drug is safer.

Study findings leave concerns beyond the changes people notice. Better sleep in an account doesn't settle the following risks.

• Benefit for healthy aging remains unproved. A medical opinion article judged the evidence too weak for that use ^[9].

The approval for children doesn't prove better health in your later years.

• Raised growth proteins leave cancer risk unanswered. Growth hormone and the liver's growth protein encourage cells to grow ^[1].

Natural limits can restrain hormone rises, but long human studies haven't settled the cancer concern.

• Older adults may have blood-sugar changes. A trial of a related, longer-lasting drug found changes in handling blood sugar ^[8].

Insulin may control blood sugar less well when growth hormone rises, which matters if you have diabetes or other blood-sugar trouble.

• A nonstop supply weakened children's hormone response. Researchers gave the drug continuously, rather than as separate daily shots ^[11].

The response faded after a few months; one child's growth-hormone release stopped entirely.

• A study shot into a vein briefly raised other hormones. Researchers found small rises in short children ^[11].

The gland makes several hormones; the effect wasn't limited to growth hormone.

• Bottles from outside pharmacies may have uncertain contents. Reports describe wrong labels, unwanted substances, and unchecked amounts ^[1].

A label alone cannot tell you what a bottle contains.

• Sport rules ban drugs that prompt growth-hormone release. Drug testing can detect this group.

People checked for drugs can face penalties for use.

Personal reports describe feelings, not proof of lasting safety. Your illnesses and medicines still matter when considering any claimed benefit.

Past child treatment does not establish safety at your age

Sermorelin once had approval for children short of growth hormone. Today's Category 1 rules let pharmacies make prescriptions under a temporary FDA policy.

The FDA doesn't plan to stop preparation that follows those rules. That permission hasn't given each pharmacy-made drug FDA approval or proved adult benefits.

The body clears sermorelin sooner than the long-acting form of CJC-1295. Natural limits on hormone release keep working, without proving years of safety.

The old trials found faster growth in the children tested. Those trials didn't test every claim made about older people's health.

CJC-1295 keeps hormones raised longer and never reached approval. Longer action can give unwanted effects more time to last.

The comparison of the drug histories explains those different findings. Neither past approval nor time in blood can predict your benefit.